Avantex Biotechnologies Inc.
  • About
    • Overview
    • Management & Directors
    • Disclaimer
  • Applications
    • Lung Cancer Application
      • – Lung Cancer Problem
      • – Lung Cancer in China
    • Eye-Care Application
    • MRI Application
    • Cannabis Applications
    • Published Research Papers
  • News
    • Industry News
    • Media Contact
  • Contact
    • Contact Information
  • Search
  • Menu Menu
APPLICATIONS

MRI Application

Avantex’s Improved MRI Contrast Agent
Avantex Biotechnologies’ proprietary macromolecular Gd-conjugated MRI contrast agent provides increased biosafety and better contrast. The Avantex’s contrast agent provides a highly precise diagnosis, which with subsequent medication will benefit patients suffering from diseases and disorders in vital organs – with a particular focus on lungs, liver and kidneys. Plus the Avantex contrast agent is much less toxic compared to existing FDA-approved Gd-based contrast substances.

Global Market – Contrast Media/Contrast Agentsa female doctor or surgeon is analysing the digitally generated scans of a human brain
The global contrast media/contrast agents market for 2015 to 2020 forecast is:

  • Expected to reach a value of $5.17 Billion by 2020, from an estimated value of $4.21 Billion in 2015. CAGR of 4.2% during that period
  • For Gd-based market only > $1 Billion in 2015

Contrast Agents and Applications
Based on products, the contrast media/contrast agents market is categorized into barium, iodinated, gadolinium, and microbubble contrast media.

  • Route of Administration – the overall market has been segmented into oral, injectable, rectal, and urethral routes. In 2015, the injectable segment is expected to account for the largest share of this market.
  • Indication – the market is segmented into cardiovascular disorders, oncology, gastrointestinal disorders, musculoskeletal disorders, neurological disorders, and nephrological disorders. In 2015, the cardiovascular disorders segment is estimated to account for the largest share of the indication market.
  • Lung Cancer Application
  • Eye-Care Application
  • MRI Application
  • – Lung Cancer Problem
  • Cannabis Applications
  • – Lung Cancer in China
  • Published Research Papers

INDUSTRY NEWS

  • Graphite Nanomaterials Reviewed for Role in Drug Delivery SystemsAugust 18, 2022 - 9:33 pm
  • Samsung invests $15 million in US biotech firm to develop core nanotechnology drug deliveryAugust 12, 2022 - 10:03 pm
  • Mesoporous silica nanoparticles: Possibilities in therapeutic developmentJuly 28, 2022 - 10:00 pm
  • How different cancer cells respond to drug-delivering nanoparticlesJuly 22, 2022 - 9:19 pm
  • What to Expect From the Launch of Cannabis Edibles in CanadaDecember 31, 2019 - 12:00 pm
  • New Cannabis Products to Follow Edibles LegalizationSeptember 5, 2019 - 12:00 pm

ABOUT
Overview
Management & Directors
Disclaimer

BIOTECH APPLICATIONS
Eye-Care Application
Lung Cancer Application
– Lung Cancer Problem
– Lung Cancer in China
Cannabis Applications
MRI Application
Research Papers

NEWS
Industry News
Media Contact

CONTACT
Contact Information

CONTACT
Nikita Chou, President
E: nchou@avantexbio.com
M: +1-778-888-3892

Ullrich Schade, VP Marketing
E: uschade@avantexbio.com
M: +1-604-644-4914

Branding by:
NextPhase Strategy

Scroll to top